Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2827656 | 0.98 | HCAR3 (0.45) | HCAR3KDM4EGAAALDH1A1HDAC3 | |
| SCHEMBL2830009 | 0.93 | HCAR3 (0.44) | HCAR3KDM4EGAAALDH1A1PKM | |
| SCHEMBL3580737 | 0.92 | HCAR3 (0.42) | HCAR3KDM4EGAAALDH1A1PKM | |
| SCHEMBL2828793 | 0.80 | SMN1; SMN2 (0.47) | MEN1TSHRKMT2A | |
| SCHEMBL3530775 | 0.79 | ALDH1A1 (0.48) | KDM4EALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL2831299 | 0.78 | ALDH1A1 (0.50) | KDM4EALDH1A1MEN1TSHRKMT2A | |
| Lithium Ion SCHEMBL3580735 | 0.77 | HCAR3 (0.35) | HCAR3KDM4EPKM | |
| SCHEMBL27724966 | 0.73 | HCAR3 (0.40) | HCAR3KDM4EGAAALDH1A1HDAC3 | |
| SCHEMBL2826097 | 0.73 | NAMPT (0.47) | MEN1TSHRKMT2A | |
| SCHEMBL2826632 | 0.72 | NPC1 (0.54) | KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844044-B1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-07-21 | — | — | EP | claimed |
| US-7678815-B2 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| EP-1844044-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | claimed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | claimed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | claimed |
| US-9988378-B2 | 1 H-pyrazole and 4,5-disubstituted thiazole inhibitors of SYK | HOFFMANN-LA ROCHE INC. (CH) | 2018-06-05 | — | — | US | disclosed |
| US-9988378-B2 | 1 H-pyrazole and 4,5-disubstituted thiazole inhibitors of SYK | HOFFMANN-LA ROCHE INC. (CH) | 2018-06-05 | — | — | US | disclosed |
| US-9988378-B2 | 1 H-pyrazole and 4,5-disubstituted thiazole inhibitors of SYK | HOFFMANN-LA ROCHE INC. (CH) | 2018-06-05 | — | — | US | disclosed |
| US-20150266874-A1 | 1 H-PYRAZOLE AND 4,5-DISUBSTITUTED THIAZOLE INHIBITORS OF SYK | HOFFMANN-LA ROCHE INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266874-A1 | 1 H-PYRAZOLE AND 4,5-DISUBSTITUTED THIAZOLE INHIBITORS OF SYK | HOFFMANN-LA ROCHE INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266874-A1 | 1 H-PYRAZOLE AND 4,5-DISUBSTITUTED THIAZOLE INHIBITORS OF SYK | HOFFMANN-LA ROCHE INC. | 2015-09-24 | — | — | US | disclosed |
| WO-2014064134-A1 | 3,4-DISUBSTITUTED 1 H-PYRAZOLE AND 4,5-DISUBSTITUTED THIAZOLE INHIBITORS OF SYK | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-01 | — | — | WO | disclosed |
| WO-2014064134-A1 | 3,4-DISUBSTITUTED 1 H-PYRAZOLE AND 4,5-DISUBSTITUTED THIAZOLE INHIBITORS OF SYK | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-01 | — | — | WO | disclosed |
| EP-1844044-B1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-07-21 | — | — | EP | disclosed |
| US-7678815-B2 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1844044-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | GRM1, GRM2, GRIA4 | HCAR3 85/4885KDM4E 1059/4885GAA 4165/4885 |
| US-20150266874-A1 | 1 H-PYRAZOLE AND 4,5-DISUBSTITUTED THIAZOLE INHIBITORS OF SYK | SYK, BTK, IRAK4 | HCAR3 1015/4885KDM4E 528/4885GAA 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.